Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   39185   clinical trials with a EudraCT protocol, of which   6421   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2017-004851-22
    Sponsor's Protocol Code Number:B7451015
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2018-09-17
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-004851-22
    A.3Full title of the trial
    A phase 3 multi-center, long-term extension study investigating the efficacy and safety of PF-04965842, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis
    Estudio en fase III multicéntrico y de extensión a largo plazo para evaluar la eficacia y la seguridad de PF-04965842, en monoterapia o en combinación con medicamentos tópicos, administrado a pacientes de 12 años o más con dermatitis atópica moderada o grave
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effective PF-04965842 are when taken as the treatment for moderate to severe atopic dermatitis in patients aged 12 years or older. Patients may also receive topical medications if needed.
    Un estudio que permite a los pacientes de estudios previous seguir con la medicación. El objetivo del estudio es determiner como de seguro y eficaz es PF-04965842 para el tratamiento de dermatitis atópica moderada o grave en pacientes de 12 años o más. Los pacientes podran recibir también medicación tópica si lo precisan.
    A.4.1Sponsor's protocol code numberB7451015
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPfizer Inc., 235 East 42nd Street, New York, NY 10017
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPfizer Inc, 235 East 42nd Street, New York, NY 10017
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPfizer Inc.
    B.5.2Functional name of contact pointClinical Trials.gov Call Centre
    B.5.3 Address:
    B.5.3.1Street Address235 East 42nd Street,
    B.5.3.2Town/ cityNew York,
    B.5.3.3Post codeNY 10017
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1 800 7181021
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePF-04965842 Tablets
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPF-04965842
    D.3.9.2Current sponsor codePF-04965842
    D.3.9.3Other descriptive namePF-04965842
    D.3.9.4EV Substance CodeSUB177174
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Moderate to severe atopic dermatitis
    Dermatitis atópica moderada o grave
    E.1.1.1Medical condition in easily understood language
    Atopic dermatitis is also known as atopic eczema. It is a type of inflammation of the skin that results in itchy, red, swollen, and cracked skin.
    La dermatitis atópica se conoce también como eccema atópico. Se trata de un tipo de inflamación de la piel que provoca picor, enrojecimiento,
    hinchazón y piel agrietada.
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10003639
    E.1.2Term Atopic dermatitis
    E.1.2System Organ Class 100000004858
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To estimate the long-term safety of 100 mg and 200 mg once daily (QD) of PF-04965842 with or without topical treatments in adult and adolescent subjects who previously participated in PF-04965842 atopic dermatitis (AD) Phase 3 trials.
    Estimar la seguridad a largo plazo de la administración de 100 mg y 200 mg una vez al día (1 v/d) de PF-04965842 con o sin tratamientos tópicos en pacientes adultos y adolescentes que habían participado previamente en ensayos en fase III con PF-04965842 para la dermatitis atópica (DA).
    E.2.2Secondary objectives of the trial
    To estimate the long-term efficacy of PF-04965842.
    Estimar la eficacia a largo plazo de PF-04965842.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Evidence of a personally signed and dated informed consent document indicating that the subject or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study.
    2. Male or female subjects of 12 years of age or older, at the time of informed consent and body weight ≥ 40 kg. Adolescent subjects below the age of 18 years old (or country-specific age of majority) will only be enrolled in this study if instructed by the sponsor and approved by the country or regulatory/health authority. If these approvals have not been granted, only subjects aged 18 years (or country-specific age of majority) and older will be enrolled.
    3. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
    4. Must have completed the full treatment period of a qualifying Phase 3 study OR must have completed the full rescue treatment period of a qualifying Phase 3 study (if applicable). OR must have completed the full open-label run-in period in B7451014 and did not meet the protocol-specified response criteria at week 12.
    5. Female subjects who are of childbearing potential (which includes all female subjects aged 12 years and older, regardless of whether they have experienced menarche) must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:
    a. Female subjects of childbearing potential must have a confirmed negative pregnancy test prior to allocation to treatment.
    b. Female subjects of childbearing potential must agree to use a highly effective method of contraception (as per Section 4.4.1) for the duration of the active treatment period and for at least 28 days after the last dose of investigational product.
    For Czech Republic only, 5 b. is revised and 5 c. is added to require:
    Female subjects of childbearing potential ≥15 years of age who are at risk of pregnancy must agree to use a highly effective method of contraception for the duration of the active treatment period and for at least 28 days after the last dose of investigational product;
    c. Female subjects less than 15 years of age must not be sexually active, and abstinence per the below definition should be confirmed prior to enrollment.
    NOTE: Sexual abstinence, defined as completely and persistently refraining from all heterosexual intercourse (including during the entire period of risk associated with the study treatments) may obviate the need for contraception ONLY if this is the preferred and usual lifestyle of the subject.
    6. Female subjects of non-childbearing potential must meet at least 1 of the following criteria:
    a. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    b. Have medically confirmed ovarian failure; or
    c. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state.
    All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
    7. Must agree to avoid prolonged exposure to the sun and not to use tanning booths, sun lamps or other ultraviolet light sources during the study.
    8. Must agree to avoid use of prohibited medications throughout the duration of the study, as detailed in Appendix 2 and Appendix 3.
    1.Constancia de un formulario de consentimiento informado firmado y fechado personalmente que indique que se ha informado al paciente o a su/sus progenitor/es o tutor legal, si procede, de todos los aspectos pertinentes del estudio.
    2.Pacientes de ambos sexos de 12 años de edad o más en el momento del consentimiento informado y con un peso corporal ≥40 kg. Los pacientes adolescentes menores de 18 años (o edad de mayoría de edad específica de cada país) solo se incluirán en este estudio si así lo solicita el promotor y si lo aprueba la autoridad reguladora/sanitaria de cada país. Si no se han concedido estas aprobaciones, solo se incluirán pacientes de 18 años (o edad de mayoría de edad específica de cada país) o más.
    3.Voluntad y capacidad de cumplir las visitas programadas, el plan de tratamiento, los análisis clínicos y otros procedimientos del estudio.
    4.Debe haber completado el periodo de tratamiento completo de un estudio en fase III habilitante O debe haber completado el periodo de tratamiento de rescate completo de un estudio en fase III habilitante (si procede) O debe haber completado el periodo de preinclusión abierto completo de B7451014 y no cumplir los criterios de respuesta especificados en el protocolo en la semana 12
    5.Mujeres con capacidad de concebir (entre las que se incluyen todas las pacientes de 12 años de edad o más con independencia de si han presentado la menarquia) que no tengan intención de quedarse embarazadas ni estén embarazadas en la actualidad ni en periodo de lactancia. Se aplican las siguientes condiciones:a.Las pacientes con capacidad de concebir deben tener un resultado negativo confirmado en la prueba de embarazo antes de la asignación al tratamiento.b:Las pacientes con capacidad de concebir deben estar de acuerdo en utilizar un método anticonceptivo altamente eficaz (de acuerdo con la sección 4.4.1 del protocolo) durante todo el periodo de tratamiento activo y durante al menos los 28 días siguientes a la administración de la última dosis del producto en investigación.
    6.Las pacientes sin capacidad de concebir deben cumplir al menos 1 de los siguientes criterios:a.haberse sometido a una histerectomía y/o a una ovariectomía bilateral documentadas;
    b.habérseles confirmado médicamente insuficiencia ovárica; o c.haber alcanzado el estado posmenopáusico, definido como: cese de la menstruación periódica durante al menos 12 meses seguidos sin ninguna otra causa patológica ni fisiológica y nivel de hormona foliculoestimulante (FSH) sérica que confirme este estado posmenopáusico. Se considera que todas las demás pacientes (incluidas las pacientes con ligadura de trompas) tienen capacidad de concebir.
    7.Debe aceptar evitar una exposición prolongada a la luz solar y el uso de cabinas o lámparas de bronceado u otras fuentes de luz ultravioleta durante el estudio.
    8.Debe aceptar evitar el uso de medicamentos prohibidos a lo largo de todo el estudio, como se indica en el Apéndice 2 y el Apéndice 3 del protocolo.
    E.4Principal exclusion criteria
    1. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
    2. Currently have active forms of other inflammatory skin diseases, ie, not AD.
    3. Have evidence of skin conditions (eg, psoriasis, seborrheic dermatitis, Lupus) at the time of Day -1 that would interfere with evaluation of atopic dermatitis or response to treatment.
    4. Discontinued from treatment (or rescue treatment period/open-label run-in period, if applicable) early in a qualifying Phase 3 study OR triggered discontinuation criteria at any point during the qualifying Phase 3 study OR meets exclusion criteria from qualifying Phase 3 studies as detailed in Appendix 10 of the protocol.
    5. Ongoing adverse event in the qualifying Phase 3 study which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the subject is currently triggering safety monitoring criteria in the qualifying Phase 3 study.
    6. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
    1.Otras enfermedades o alteraciones psiquiátricas, agudas o crónicas, incluidos los comportamientos o las ideas suicidas recientes (en el último año) o activos, o anomalías de laboratorio que puedan aumentar el riesgo asociado a la participación en el estudio o a la administración del producto en investigación, o que puedan interferir con la interpretación de los resultados del estudio y que, según el criterio del investigador, hagan que el paciente no sea apto para incorporarse al estudio.
    2.Pacientes que actualmente presentan formas activas de otras enfermedades inflamatorias de la piel, es decir, que no sean DA.
    3.Pacientes que presentan signos de enfermedades cutáneas (p. ej., psoriasis, dermatitis seborreica, lupus) en el momento del Día −1 que pudieran interferir en la evaluación de la dermatitis atópica o en la respuesta al tratamiento.
    4.Pacientes discontinuados del tratamiento (o del periodo de tratamiento de rescate/periodo de preinclusión abierto, si procede) en una etapa temprana de un estudio en fase III habilitante O pacientes que cumplieron los criterios de discontinuación en cualquier momento durante el estudio en fase III habilitante O que cumplen los criterios de exclusión del estudio en fase III habilitante, como se indica en el Apéndice 10 del protocolo.
    5.Pacientes con un acontecimiento adverso en curso en el estudio en fase III habilitante que, en opinión del investigador o del promotor, sea un problema de seguridad en curso O pacientes que cumplan en la actualidad los criterios para la activación de la monitorización de la seguridad en el estudio en fase III habilitante.
    6.Pacientes que sean miembros del personal del centro del investigador directamente implicados en la realización del estudio, así como sus familiares; miembros del personal del centro supervisados de alguna otra manera por el investigador o pacientes que sean empleados de Pfizer, incluidos los miembros de su familia, y que estén directamente implicados en la realización del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    Primary (Safety) Endpoints
    • The incidence of treatment emergent adverse events.
    • The incidence of serious adverse events and adverse events leading to discontinuation.
    • The incidence of clinical abnormalities and change from baseline in clinical laboratory values, electrocardiogram (ECG) measurements, and vital signs.
    •La incidencia de los eventos adversos emergentes del tratamiento.
    • La incidencia de eventos adversos graves y eventos adversos que conducen a la interrupción.
    • La incidencia de anomalías clínicas y cambios en los valores clínicos de laboratorio, las mediciones del electrocardiograma (ECG) y los signos vitales des de el inicio.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Through out the study
    Durante todo el estudio.
    E.5.2Secondary end point(s)
    Baseline, for efficacy endpoints, is defined as pre-dose Day 1 in the qualifying Phase 3 study.
    • Response based on achieving the Investigator’s Global Assessment (IGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥ 2 points at all scheduled time points.
    • Response based on achieving ≥ 50%, ≥ 75% and ≥ 90% improvement from baseline in the Eczema Area and Severity Index (EASI) total score (EASI50, EASI75, and EASI90) at all scheduled time points.
    • Response based on achieving an improvement ≥ 4 points from baseline in the severity of pruritus NRS at all scheduled time points.
    • Change from baseline in the frequency of itching due to Atopic Dermatitis
    • Change from baseline of Patient Global Assessment (PtGA) at all scheduled time points.
    • Change from baseline in the percentage Body Surface Area (BSA) affected at all scheduled time points.
    • Change from baseline in Dermatology Life Quality Index (DLQI) or Children’s DLQI (CDLQI) at all scheduled time points.
    • Change from baseline in Patient Oriented Eczema Measure (POEM) at all scheduled time points.
    • Change from baseline in Hospital Anxiety and Depression Scale (HADS) at all scheduled time points.
    • Change from baseline of EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) or EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) at all scheduled time points.
    • Steroid-free days.
    Visita Basal, para los criterios de valoracion de eficacia, se define como pre-dosis Dia 1 en el estudio Fase III habilitante
    -Respuesta basada en la puntuación de la evaluación global del investigador (EGI) de 0 o casi cero (1) (en una escala de 5 puntos) y una reducción des del principio de ≥ 2 puntos en todos los puntos temporales programados.
    -Respuesta basada en alcanzar una mejoría de ≥ 50%, ≥ 75% y ≥ 90% des del principio en la área de eccema y puntuación total de EASI (EASI50, EASI75, and EASI90) en todos los puntos temporales programados
    -Respuesta basada en alcanzar una mejoría de ≥ 4 puntos desde el principio en la severidad del prurito NRS en todos los puntos temporales programados
    -Cambio desde visita basal en la frecuencia de picores debido a Dermatitis Atopica
    -Cambio desde visita basal en la Evaluación Global del paciente (PtGA) en todos los puntos temporales programados
    -Cambio desde visita basal en el porcentaje del Area de Superficie corporal afectada (ASC) en todos los puntos temporales programados
    -Cambio desde visita basal en el índice Dermatologico de calidad de vida (DLQI) o en el DLQI pediátrico (CDLQI) en todos los puntos temporales programados
    -Cambio desde visita basal en la Escala de medicion del eccema orientada al paciente (POEM) en todos los puntos temporales programados
    -Cambio desde visita basal en la escala hospitalaria de ansiedad y depresión (HADS) en todos los puntos temporales programados
    -Cambio desde visita basal en las escalas EuroQol de calidad de vida de 5 dimensiones y 5 niveles (EQ-5D-5L) y EuroQol de calidad de vida de 5 dimensiones-escala versión juvenil (EQ-5D-Y) en todos los puntos temporales programados
    -Dias sin esteroides
    E.5.2.1Timepoint(s) of evaluation of this end point
    At all scheduled timepoints
    En todos los puntos temporales programados.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned15
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA36
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Czech Republic
    Korea, Republic of
    Russian Federation
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of trial in a Member State of the EU is defined as the time at which it is deemed that a sufficient number of subjects have been recruited and completed the study as stated in the regulatory application (ie, clinical trial application [CTA]) and ethics application in the Member State. Poor recruitment (recruiting less than the anticipated number in the CTA) by a Member State is not a reason for premature termination but is considered a normal conclusion to the study in that Member State.
    El final del ensayo en un Estado Miembro de la UE se define como el momento en el que se considera que se ha reclutado a un número suficiente de pacientes y estos han finalizado el estudio según lo declarado en el CTA presentado para la Agencia y para el CEIC del Estado Miembro. Un reclutamiento inferior al número previsto en el CTA por parte de un Estado miembro no es un motivo de terminación prematura, pero se considera una conclusión normal del estudio en ese Estado miembro.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 290
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F. of subjects for this age range: 290
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1780
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 230
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    Whenever consent is obtained from a subject's parent(s)/legal guardian, the subject's assent (affirmative agreement) must subsequently be obtained.
    Siempre que se obtenga el consentimiento del/de los progenitor/es o tutor legal del paciente, deberá obtenerse posteriormente el asentimiento (acuerdo afirmativo) del paciente.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state90
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1800
    F.4.2.2In the whole clinical trial 2300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-11-15
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-10-22
    P. End of Trial
    P.End of Trial StatusOngoing
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice